Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer

Int J Urol. 2002 Jun;9(6):359-61. doi: 10.1046/j.1442-2042.2002.00476.x.

Abstract

A 75-year-old man with metastatic prostate cancer had been treated with goserelin acetate, and prostate specific antigen (PSA) had decreased, but 11/2 years after beginning the treatment of goserelin acetate, PSA was markedly elevated and serum testosterone was at normal level. After castration the serum testosterone was at castrate level and PSA decreased. In the present case, leuprorelin acetate 1-month depot suppressed the luteinizing hormone level in 1 month, even after the patient underwent castration.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / blood*
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / surgery
  • Aged
  • Fertility Agents, Female / agonists*
  • Fertility Agents, Female / therapeutic use*
  • Gonadal Steroid Hormones / antagonists & inhibitors*
  • Gonadal Steroid Hormones / blood*
  • Gonadotropin-Releasing Hormone / agonists*
  • Gonadotropin-Releasing Hormone / therapeutic use*
  • Humans
  • Male
  • Orchiectomy
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / surgery
  • Testosterone / antagonists & inhibitors*
  • Testosterone / blood*
  • Treatment Failure

Substances

  • Fertility Agents, Female
  • Gonadal Steroid Hormones
  • Gonadotropin-Releasing Hormone
  • Testosterone